Physician profile
Eric M Speare
NPI 1306984570
$7,022.78
in general payments reported to CMS, 2019-2025
31 companies · $950 in 2025
The $950 reported for 2025 was more than what 80% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $664 · 2020: $765 · 2021: $1,286 · 2022: $1,744 · 2023: $1,085 · 2024: $528 · 2025: $950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,563.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,042.62 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $724.98 | 2019-2025 | Spravato, Invega Trinza, Invega |
| Vanda Pharmaceuticals INC. | $635.61 | 2019-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $610.56 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Alkermes, INC. | $574.10 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Sunovion Pharmaceuticals INC. | $559.71 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $344.91 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $297.88 | 2019-2023 | Trintellix |
| Neurocrine Biosciences, INC. | $250.66 | 2021-2023 | Ingrezza |
| Lundbeck LLC | $244.81 | 2020-2025 | Rexulti, Brintellix |
| Allergan, INC. | $187.62 | 2019-2020 | |
| Axsome Therapeutics, INC. | $159.35 | 2022-2025 | Auvelity |
| Adlon Therapeutics L.P. | $159.03 | 2019-2021 | |
| Bausch Health US, LLC | $147.61 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $139.19 | 2024-2025 | Cobenfy |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $132.38 | 2020-2022 | |
| Almatica Pharma LLC | $129.98 | 2023-2024 | Loreev Xr, Sertraline Hcl |
| Ironshore Pharmaceuticals INC. | $109.81 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $101.72 | 2023-2024 | Austedo Xr, Uzedy |
| Alfasigma USA, INC. | $88.11 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $55.42 | 2019 | |
| Idorsia Pharmaceuticals US INC | $50.88 | 2023 | Quviviq |
| Corium, LLC | $46.77 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $43.38 | 2025 | |
| Nalpropion Pharmaceuticals LLC | $40.30 | 2019 | |
| Merck Sharp & Dohme LLC | $35.54 | 2020 | |
| Noven Therapeutics, LLC | $24.55 | 2022 | |
| Collegium Pharmaceutical, INC. | $24.24 | 2025 | Jornay Pm |
| Indivior INC. | $23.87 | 2022 | |
| Biogen, INC. | $18.68 | 2022 | |
| Luye Pharma (USA) LTD. | $18.51 | 2025 | Erzofri Extended-Release |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Speare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.